论文部分内容阅读
目的探讨倍他乐克治疗慢性充血性心力衰竭临床疗效及不良反应。方法将收治的慢性充血性心力衰竭73例随机分为治疗组(37例)和对照组(36例),两组均给予常规抗心衰治疗,治疗组加用倍他乐克6.25mg/d始,缓慢加量到有效剂量达25～50mg/d,6周为一疗程,观察症状、体征及心率和心功能改善状况。结果治疗组患者症状和体征消失及改善率、心率降低和心功能改善率明显优于对照组(P<0.01)。结论倍他乐克可作为治疗病情稳定的慢性充血性心力衰竭患者的首选药物之一。
Objective To investigate the clinical efficacy and adverse reactions of Betaloc in the treatment of chronic congestive heart failure. Methods Seventy-three patients with chronic congestive heart failure were randomly divided into treatment group (37 cases) and control group (36 cases). Both groups were given routine anti-heart failure treatment. The treatment group was treated with betameto 6.25 mg / d Start, slow dosage to an effective dose of 25 ~ 50mg / d, 6 weeks for a course of treatment, observe the symptoms, signs and heart rate and heart function to improve the situation. Results The symptoms and signs disappeared and the improvement rate, heart rate and heart function improvement rate in the treatment group were significantly better than those in the control group (P <0.01). Conclusion Betaloc can be one of the preferred drugs for the treatment of stable patients with chronic congestive heart failure.